Target Name: RTN4RL2
NCBI ID: G349667
Review Report on RTN4RL2 Target / Biomarker Content of Review Report on RTN4RL2 Target / Biomarker
RTN4RL2
Other Name(s): Nogo receptor-like 3 | Nogo-66 receptor-related protein 2 | NgR2 | NGRL3 | NGRH1 | nogo-66 receptor-related protein 2 | Reticulon 4 receptor like 2 | reticulon 4 receptor like 2 | Nogo-66 receptor homolog 1 | Reticulon-4 receptor-like 2 | R4RL2_HUMAN | nogo receptor-like 3

RTN4RL2 Receptor: for Pain Modulation, NeuroProtection and NeuroTransmission

The Nogo receptor-like 3 (RTN4RL2) is a G protein-coupled receptor that is expressed in various tissues and plays an important role in pain modulation, neuroprotection, and neurotransmission. The RTN4RL2 receptor has been identified as a potential drug target and a biomarker for various neurological and psychiatric disorders, including chronic pain, neurodegenerative diseases, and neuropsychiatric disorders. In this article, we will discuss the RTN4RL2 receptor, its function, potential drug targets, and its potential as a biomarker.

Function of RTN4RL2

The RTN4RL2 receptor is a G protein-coupled receptor that is expressed in various tissues, including the central nervous system, peripheral nervous system, and skeletal muscles. The RTN4RL2 receptor is involved in pain modulation, neuroprotection, and neurotransmission.

Pain Modulation

RTN4RL2 is involved in pain modulation and has been shown to play an important role in the regulation of pain perception. Studies have shown that activation of the RTN4RL2 receptor can inhibit pain perception and reduce pain sensitivity. Additionally, blockade of the RTN4RL2 receptor has been shown to provide pain relief in various pain models, including neuropathic pain and chronic pain.

NeuroProtection

RTN4RL2 has also been shown to play an important role in neuroprotection. Studies have shown that activation of the RTN4RL2 receptor can promote neuroprotective enzymes, such as superoxide dismutase (SOD) and catalase (CAT), which can help to protect against oxidative stress and neurotoxicity . Additionally, blockade of the RTN4RL2 receptor has been shown to protect against neurotoxicity in various models, including neurofibromatosis and neurodegenerative diseases.

NeuroTransmission

RTN4RL2 is involved in neurotransmission and has been shown to play an important role in the regulation of neurotransmitter release. Studies have shown that activation of the RTN4RL2 receptor can increase neurotransmitter release, including dopamine (DA), GABA, and serotonin (5-HT) . Additionally, blockade of the RTN4RL2 receptor has been shown to modulate neurotransmission in various models, including neuropathic pain and chronic pain.

Potential Drug Targets

RTN4RL2 has been identified as a potential drug target due to its involvement in pain modulation, neuroprotection, and neurotransmission. Several small molecules have been shown to be potent RTN4RL2 antagonists, including P16, a potent inhibitor of the RTN4RL2 receptor, and Uprotect, a small molecule that blocks the activity of the RTN4RL2 receptor.

RTN4RL2 has also been shown to interact with several other proteins, including GABA receptors, which can modulate neurotransmission. Additionally, studies have shown that the RTN4RL2 receptor can interact with several other G protein-coupled receptors, including GLT-1, which can modulate insulin sensitivity and inflammation.

Potential as a Biomarker

RTN4RL2 has been shown to be a potential biomarker for various neurological and psychiatric disorders, including chronic pain, neurodegenerative diseases, and neuropsychiatric disorders. The RTN4RL2 receptor is expressed in various tissues and can be used as a biomarker for these disorders.

Chronic Pain

RTN4RL2 has been shown to be involved in the regulation of chronic pain. Studies have shown that activation of the RTN4RL2 receptor can increase pain perception and reduce pain tolerance. Additionally, blockade of the RTN4RL2 receptor has been shown to provide relief from chronic pain in various models.

Neurodegenerative Diseases

RTN4RL2 has also been shown to be involved in the regulation of neurodegenerative diseases. Studies have shown that activation of the RTN4RL2 receptor can promote neurotoxicity and neurodegeneration in various models, including neurofibromatosis and Alzheimer's disease. Additionally, blockade of the RTN4RL2 receptor has been shown to protect against neurotoxicity in various models, including neurodegenerative diseases.

Neuropsychiatric Disorders

RTN4RL2 has also been shown to be involved in the regulation of neuropsychiatric disorders. Studies have shown that activation of the RTN4RL2 receptor can modulate neurotransmission in various models, including

Protein Name: Reticulon 4 Receptor Like 2

Functions: Cell surface receptor that plays a functionally redundant role in the inhibition of neurite outgrowth mediated by MAG (By similarity). Plays a functionally redundant role in postnatal brain development. Contributes to normal axon migration across the brain midline and normal formation of the corpus callosum. Does not seem to play a significant role in regulating axon regeneration in the adult central nervous system. Protects motoneurons against apoptosis; protection against apoptosis is probably mediated by MAG (By similarity). Like other family members, plays a role in restricting the number dendritic spines and the number of synapses that are formed during brain development (PubMed:22325200). Signaling mediates activation of Rho and downstream reorganization of the actin cytoskeleton (PubMed:22325200)

The "RTN4RL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RTN4RL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RTP1 | RTP2 | RTP3 | RTP4 | RTP5 | RTRAF | RTTN | RUBCN | RUBCNL | RUFY1 | RUFY2 | RUFY3 | RUFY4 | RUNDC1 | RUNDC3A | RUNDC3A-AS1 | RUNDC3B | RUNX1 | RUNX1-IT1 | RUNX1T1 | RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P | S100PBP | S100Z | S1PR1 | S1PR1-DT | S1PR2 | S1PR3 | S1PR4 | S1PR5 | SAA1 | SAA2 | SAA2-SAA4 | SAA3P | SAA4 | SAAL1 | SAC3D1 | SACM1L | SACS | SACS-AS1 | SAE1 | SAFB | SAFB2 | SAG | SAGA complex | SAGE1 | SALL1